IPSEN (OTCMKTS:IPSEY – Get Free Report) is expected to issue its resultson Thursday, July 30th. Analysts expect the company to announce earnings of $1.86 per share and revenue of $2.4202 billion for the quarter.
IPSEN Price Performance
Shares of IPSEY opened at $44.81 on Wednesday. The company has a 50-day simple moving average of $46.04 and a 200-day simple moving average of $45.37. IPSEN has a 52 week low of $30.05 and a 52 week high of $51.10.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the company. Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Finally, HC Wainwright restated a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.
IPSEN Company Profile
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Featured Stories
- Five stocks we like better than IPSEN
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
